Filing Flows

Filing Flows › 8-K events › iSpecimen

iSpecimen: change in control

Form 8-K filed Nov 5, 2026 · items 1.01, 2.01, 3.02, 5.01, 7.01

Changes in controliSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products

What the filing says

The information set forth in Items 1.01, 2.01 and 3.02 of this Current Report on Form 8-K is incorporated herein by reference. As a result of the issuance of the Stock Consideration on November 5, 2026, Foldlab acquired 2,907,977 shares of Common Stock, representing approximately 53.6% of the outstanding shares of Comm

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.01: +0.1% next session across 2,671. Item 3.02: +0.1% next session across 2,750. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.

Item 5.01 — Change in control. A change in control: someone now controls the company.

iSpecimen at a glance

Latest quarterQ2 2026
Revenue$152K
Revenue Y/Y-79%
Operating margin-897.1%
IndustryServices-Commercial Physical & Biological Research

iSpecimen, Q2 2026: revenue $152K (-79% year over year), operating margin -897.1%. The chart follows the revenue to costs, profit and cash.

iSpecimen: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent changes in control

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.